RxDoctor Payments Data

Ravish Narvel, MD

Internal Medicine · Jacksonville, FLNPI 1124088604

Payments from drug & device makers

$1,192in general payments, 2019–2025

Across 29 payments — averaging $41.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$213
  • Lilly USA, LLC$187
  • Madrigal Pharmaceuticals$133
  • Heartflow, Inc.$130
  • Vapotherm Inc$123
  • AstraZeneca$120
  • plus $286 from 7 others

What the payments were for

  • Food & beverage$99483%
  • Education$19817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,192 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$575,874
Medicare patients
567
Services billed
6,911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban568$280,622
JanuviaSitagliptin Phosphate190$73,390
OzempicSemaglutide58$69,726
TrulicityDulaglutide40$37,849
JardianceEmpagliflozin72$33,318
MounjaroTirzepatide27$32,985
TradjentaLinagliptin56$29,154
FarxigaDapagliflozin Propanediol36$26,120
EntrestoSacubitril/Valsartan41$25,644
XifaxanRifaximin15$24,450
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,436
MyrbetriqMirabegron28$18,106
Gabapentin737$15,447
Potassium Chloride561$14,878
Atorvastatin Calcium872$14,778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$280,622568 claims
MerckJanuvia$18$73,390190 claims
Lilly USA, LLCTrulicity, Mounjaro$187$70,83567 claims
Novo NordiskOzempic$44$69,72658 claims
AstraZenecaFarxiga$120$26,12036 claims
Astellas Pharma US IncMyrbetriq$213$18,10628 claims
Johnson & JohnsonXarelto$90$13,01532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →